Live Breaking News & Updates on Project baseline

Stay informed with the latest breaking news from Project baseline on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Project baseline and stay connected to the pulse of your community

SKNVibes | St. Kitts & Nevis National Council on Drug Abuse Prevention provides training on Cannabis Youth Treatment Programme

SKNVibes | St. Kitts & Nevis National Council on Drug Abuse Prevention provides training on Cannabis Youth Treatment Programme
sknvibes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sknvibes.com Daily Mail and Mail on Sunday newspapers.

Basseterre , Saint-george-basseterre , Saint-kitts-and-nevis , Mexico , United-states , American , Karimu-byron-caines , Zahra-jacobs , Sandra-maynard , Zahnela-claxton , Department-of-education-on-nevis , National-council-on-drug-abuse-prevention

Silicon Valley and WEF-Backed Foundation Announce Global Initiative for COVID-19 Vaccine Records

Silicon Valley and WEF-Backed Foundation Announce Global Initiative for COVID-19 Vaccine Records
unlimitedhangout.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from unlimitedhangout.com Daily Mail and Mail on Sunday newspapers.

Switzerland , California , United-states , Israel , America , Israeli , American , Swiss , David-milliband , Jeffrey-epstein , Sergey-brin , Anne-wojcicki

Otsuka exec on what's next for kidney care innovation and a peek at what's coming down the pipeline

(Photo credit: Getty Images/Westend61)
Over the last year, digital has transformed the caregiver experience, but pharma has also been undergoing a metamorphosis in order to reach patients.
During the pandemic, life science companies were pushed to reconfigure their care in order to meet the needs of some of the most at-risk patients.
MobiHealthNews sat down with the leader of pharma giant Otsuka's Global Clinical Development on Nephrology, Dr. Charlotte Jones-Burton, to talk about innovating for rare disease, digital in clinical trials and lessons learned from past tech partnerships.
One of Otsuka's treatment areas focuses on autosomal dominant polycystic kidney disease (ADPKD), a genetic disease that requires substantial monitoring. There have always been challenges for patients living with this disease, which have been exacerbated during the pandemic.

Abilify-mycite , Charlotte-jones-burton , Otsuka-global-clinical-development-on-nephrology , Global-clinical-development , Monitoring-tool , Click-therapeutics , Project-baseline , சார்லோட்-ஜோன்ஸ்-பர்டன் , ஓத்சுக்-உலகளாவிய-மருத்துவ-வளர்ச்சி-ஆன்-நெப்ராலஜி , உலகளாவிய-மருத்துவ-வளர்ச்சி , கண்காணிப்பு-கருவி , கிளிக்-செய்க-சிகிச்சை

Otsuka launches pivotal trial of digital therapeutics for depression

MedCity News
Otsuka launches pivotal trial of digital therapeutics for depression
Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms.
Shares0
Otsuka Pharmaceutical is launching a virtual study to see if digital therapeutics can reduce depression symptoms.
It’s the next step in a partnership between the Tokyo-based drugmaker and Click Therapeutics, a digital health startup that is developing programs for smoking cessation, depression and insomnia.
They plan to enroll up to 540 patients in a randomized, controlled trial that will test the digital therapeutic’s efficacy in patients that are taking antidepressants. The remote trial will be conducted using Verily’s Project Baseline platform.

Tokyo , Japan , Abilify-mycite , Christoph-koenen , Click-therapeutics , Project-baseline , Asberg-depression-rating-scale , Chief-medical-officer-christoph-koenen , Proteus-therapeutics , Weight-loss , Obesity

Verily's covid-testing partnership with California is over

Google sister Verily was touted early in the pandemic as a promising coronavirus testing option.

California , United-states , Spain , Washington , White-house , District-of-columbia , San-francisco , Spanish , Deborah-birx , Google , Washington-post , Trump-administration

Fierce Pharma Asia—Daiichi Sankyo's new R&D head; Clover's $230M raise; Insilico's AI breakthrough

Daiichi Sankyo, Clover Biopharmaceuticals and Insilico Medicine made our news this week. (Google)
Amid a big cancer push, Daiichi Sankyo lured Kite Pharma exec Ken Takeshita to lead its R&D work. China's Clover Biopharmaceuticals secured $230 million in an oversubscribed series C to help advance its COVID-19 vaccine program and expand manufacturing capabilities. In several firsts for artificial-intelligence-based drug discovery, Insilico Medicine discovered a novel target for idiopathic pulmonary fibrosis, designed a new molecule and validated it in preclinical models in 18 months. And more.
Daiichi Sankyo, on its way to becoming a major cancer player, has poached Ken Takeshita, M.D., from Gilead Sciences’ cell therapy unit Kite Pharma to be its new global head of development and interim head of research, effective April 1. He takes over from Junichi Koga, Ph.D., who will retire after 12 years. The Japanese pharma has said it intends to develop seven new molecular entities from 2018 to 2025, with antibody-drug conjugates such as Enhertu the most prominent.

China , Japan , India , South-korea , United-kingdom , Telangana , Andhra-pradesh , Japanese , Chinese , British , Korea , Ken-takeshita

Otsuka, Click Therapeutics kick off decentralized pivotal trial for depression digital therapeutics

Share
Otsuka Pharmaceutical and Click Therapeutics have announced the launch of a new, fully remote clinical trial being conducted on Verily's Project Baseline platform.
Called the Mirai study, it will be measuring a digital therapeutics intervention's effectiveness in reducing symptoms of depression among adults who have a major depressive disorder (MDD) diagnosis and are on antidepressant monotherapy.
Christoph Koenen, EVP and chief medical officer of Ostuka Pharmaceutical Companies U.S.,
told MobiHealthNews that the pivotal, randomized, controlled trial will enroll as many as 540 patients across the country over 10 weeks of active participation. The study will be measuring safety and participants' change from baseline on the Montgomery-Åsberg Depression Rating Scale, a standardized measure of depressive symptoms.

Abilify-mycite , Christoph-koenen , Proteus-digital-health , Boehringer-ingelheim , Spencer-health-solutions , Ostuka-pharmaceutical-companies , Otsuka-pharmaceutical , Click-therapeutics , Project-baseline , Depression-rating-scale , Proteus-digital , Swedish-pharma

Gmail finally reveals all data it collects from phone users, adds privacy labels to iOS app

Gmail finally reveals all data it collects from phone users, adds privacy labels to iOS app
After YouTube, Gmail now becomes the second most important Google app to get a privacy label.
Ankita Chakravarti | February 23, 2021 | Updated 09:17 IST
Highlights
Google took a very long time to add labels to its major apps.
After YouTube, Gmail now becomes the second most important Google app to get a privacy label.
Google has finally added privacy labels to the Gmail app on Apple App Store. Google took a very long time to add labels to its major apps. After YouTube, Gmail now becomes the second most important Google app to get a privacy label. Some of the popular Google apps that are widely used by iPhone users including Gmail, Google search, Photos, Docs, and YouTube.

Google , Youtube , Facebook , Apple-app , App-privacy , Google-account , Google-translate , Google-authenticator , Google-play-movies , Google-classroom , Google-fiber

This cutting-edge cloud-computing service is helping researchers track COVID's spread

The platform's creation, says Anthony Philippakis, chief data officer at the Broad Institute, was driven by two trends within the wider biomedical space: an explosion in the volume and types of data available – from genomics data to medical imaging and electronic health records – alongside a greater need for data sharing within biomedical science.
SEE:
(TechRepublic)
"No one organisation, whether it be a medical centre, or a university, or a company, has enough data in order to go after profound questions like the genetic basis of the disease," he says.
"For a long time, although we've embraced the idea of data sharing, especially in genomics, and in many other fields, the way we've operationalized, it is a bit silly – which is to say that, in order to share data, we have to copy it: we put copies on servers and tell researchers to download it to their local environment," he explains.

Boston , Massachusetts , United-states , Nigeria , Senegal , Institute-park , Sierra-leone , Anthony-philippakis , Desney-tan , David-glazer , Google , Broad-institute

Verily joins with Janssen, adding Covid-19 to Project Baseline study

Verily joins with Janssen, adding Covid-19 to Project Baseline study
Verily and Janssen say studying Covid-19 immune responses could yield data that helps clinicians treat the disease. They add that the research could also apply to other illnesses caused by respiratory pathogens.
Shares0

When Verily unveiled $700 million in funding late last year, it said the cash would support its Covid-19 research. Some of those research plans are now taking shape.
Verily, the life sciences division of Google parent company Alphabet, is adding Covid-19 to Project Baseline, an expansive study collecting health data from thousands of patient volunteers and following them over time to create a comprehensive map of human health. The patient information contributes to a database that could offer insight into the biological drivers of health and illness.

James-merson , Jessica-mega , Google , Janssen-research-development , Novartis , Pfizer , Baseline-antibody-research , Johnson , Duke-university , Stanford-university , Project-baseline , Janssen-research